Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4003476 | 1.00 | MGLL (0.33) | MGLL | |
| SCHEMBL37884 | 0.88 | MGLL (0.36) | MGLL | |
| SCHEMBL20404645 | 0.88 | MGLL (0.36) | MGLL | |
| SCHEMBL111364 | 0.88 | MGLL (0.36) | MGLL | |
| SCHEMBL18908274 | 0.84 | MGLL (0.35) | MGLL | |
| SCHEMBL13551294 | 0.84 | MGLL (0.35) | MGLL | |
| SCHEMBL13463250 | 0.82 | MGLL (0.34) | MGLL | |
| SCHEMBL22954473 | 0.82 | MGLL (0.34) | MGLL | |
| SCHEMBL12092206 | 0.82 | MGLL (0.34) | MGLL | |
| SCHEMBL258692 | 0.82 | MGLL (0.36) | MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538129-B2 | modeled after unique toxins extracted from marine invertebrate Diazona angulata; antimitotic, antiproliferative and anticarcinogenic agents; to treat in particular Taxol (TM) -resistant cancers | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2009-05-26 | — | — | US | disclosed |
| US-20070149583-A1 | Diazonamide a analog | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149583-A1 | Diazonamide a analog | GLS, PKD1, PKD2 | MGLL 4565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.